Cannabinoids, the active components of marijuana and their derivatives, induce tumor regression in rodents (8). However, the mechanism of cannabinoid antitumoral action in vivo is as yet unknown. Here we show that local administration of a nonpsychoactive cannabinoid to mice inhibits angiogenesis of malignant gliomas as determined by immunohistochemical analyses and vascular permeability assays. In vitro and in vivo experiments show that at least two mechanisms may be involved in this cannabinoid action: the direct inhibition of vascular endothelial cell migration and survival as well as the decrease of the expression of proangiogenic factors (vascular endothelial growth factor and angiopoietin-2) and matrix metalloproteinase-2 in the tumors. Inhibition of tumor angiogenesis may allow new strategies for the design of cannabinoid-based antitumoral therapies.
C annabinoids, the active components of Cannabis sativa L. (marijuana) and their derivatives, exert a wide array of effects on the central nervous system as well as on peripheral sites such as the immune, cardiovascular, digestive, reproductive, and ocular systems (1, 2) . It is now widely accepted that most of these effects are mediated by the activation of specific G protein-coupled receptors that are normally bound by a family of endogenous ligands--the endocannabinoids (3) (4) (5) . Marijuana and its derivatives have been used in medicine for many centuries, and currently there is a renaissance in the study of the therapeutic effects of cannabinoids, which constitutes a widely debated issue with ample scientific and social relevance. Ongoing research is determining whether cannabinoid ligands may be effective agents in the treatment of pain and inflammation, glaucoma, neurodegenerative disorders such as multiple sclerosis and Parkinson's disease, and the wasting and emesis associated with acquired immunodeficiency syndrome and cancer chemotherapy (1, 2, 6) . In addition, cannabinoids might be antitumoral agents owing to their ability to induce the regression of various types of tumors in animal models (7) (8) (9) (10) . Although cannabinoids directly induce apoptosis or cell cycle arrest in different transformed cells in vitro (11, 12) , the involvement of this and other mechanisms in their antitumoral action in vivo is as yet unknown.
To grow beyond minimal size, tumors must generate a new vascular supply for purposes of gas exchange, cell nutrition, and waste disposal (13) . They do so by secreting proangiogenic cytokines that promote the formation of blood vessels. Vascular endothelial growth factor (VEGF) is considered the most important proangiogenic molecule because it is expressed abundantly by a wide variety of animal and human tumors and because of its potency, selectivity for endothelial cells, and ability to regulate most and perhaps all the steps in the angiogenic cascade (13) (14) (15) . Other cellular mediators such as the angiostatic factors angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) also control the process of angiogenesis (13) (14) (15) . Growing tumors also produce matrix metalloproteinases (MMPs) that allow tissue breakdown and remodeling during angiogenesis and invasiveness (16) . Because overexpression of proangiogenic factors and MMPs is causally involved in the progression of the majority of solid tumors, considerable effort is being made in developing effective antiangiogenic drugs (17) and MMP inhibitors (18) to treat cancer. This background prompted us to explore whether inhibition of angiogenesis is implicated in the antitumoral effect of cannabinoids. Here, we report that cannabinoid administration inhibits tumor angiogenesis in vivo and that at least two mechanisms may be involved in this action: direct inhibition of vascular endothelial cell migration and survival as well as suppression of proangiogenic factor and MMP expression in the tumors.
MATERIALS AND METHODS

Cannabinoids
JWH-133 was prepared in Dr. J.W. Huffman's laboratory (19) . HU-210 was kindly given by Dr. R. Mechoulam (Hebrew University, Jerusalem, Israel). WIN-55,212-2 and ∆ 9 -tetrahydrocannabinol were from Sigma (St. Louis, MO). SR141716 and SR144528 were kindly given by Sanofi-Synthelabo (Montpellier, France). Stock solutions of cannabinoid ligands were prepared in dimethyl sulfoxide (DMSO). For in vitro incubations, cannabinoids were directly applied at a final DMSO concentration of 0.1-0.2% (v/v). For in vivo experiments, cannabinoids were prepared at 1% (v/v) DMSO in 100 µl phosphate-buffered saline (PBS) supplemented with 5 mg/ml bovine serum albumin. No significant influence of the vehicle was observed on any of the parameters determined.
Endothelial cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical veins (20) and grown on gelatin-coated dishes in medium 199 supplemented with 20% fetal calf serum (FCS), 0.05% endothelial cell growth factor, and 100 µg/ml heparin. Cells were used between passages 4 and 7. Twenty-four hours before the experiments, cells were transferred to medium 199 plus 2% FCS. The ECV304 cell line was grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS. Twenty-four hours before the experiments, cells were transferred to serum-free DMEM plus 0.5% FCS.
Endothelial cell migration
Cell migration was routinely monitored using the Boyden chamber. After exposure to cannabinoids for 18 h, a time at which cannabinoid-induced apoptosis does not yet occur (data not shown), cells were trypsinized, washed, and loaded into the upper well. Lysophosphatidic acid (10 µM) was placed in the lower well as a cell migration stimulator. Cells were allowed to migrate for 3 h at 37°C through a Falcon 5-µm filter. Then, cells from the upper side of the membrane were removed, and the remaining cells on the bottom side of the membrane were fixed with 50% ethanol, stained with eosin blue, and counted. In other experiments, cell migration was assessed by counting the number of cells that had covered a scratch directly made on the culture dish.
Endothelial cell death
Cell viability was determined by Trypan blue exclusion. Apoptosis was determined by TUNEL staining (8) and oligonucleosomal DNA fragmentation (21) after treatment with cannabinoids and other effectors for 48 h.
Tumor induction
Gliomas were induced in mice deficient in recombination activating gene 2 by s.c. flank inoculation of tumor cells (8) . When tumors had reached a volume of 200-300 mm 3 , animals were assigned randomly to two groups and injected intratumorally with vehicle or 50 µg d -1 of JWH-133 for 8 days (rat C6 glioma cells) or 25 days (human grade IV astrocytoma cells [glioblastoma multiforme] obtained from tumor biopsies as previously described [9] ).
Histopathology and immunohistochemistry
Tumors were fixed in 10% buffered formalin and embedded in paraffin. Sections were stained with hematoxylin/eosin for histopathological evaluation. For immunohistochemistry, tumor sections were treated as previously described (22) and stained with antibodies against CD31 (Pharmigen, San Diego, CA) and SMA (Sigma, St. Louis, MO).
Vascular permeability assay
Vascular permeability was assessed using a modified Miles assay. Tumor-bearing animals were anesthesized and Evans blue (1% in PBS, 100 µl/mouse) was injected into the tail vein. Dye leakage was subsequently detected as blue spots on the tumor surface.
VEGF, Ang1, and Ang2 expression
Total RNA was extracted from the tumor samples by the acid-guanidinium method (22) . The anti-VEGF probe has been described previously (22) . Probes for Ang1 and Ang2 detection were kindly provided by Dr. G. D. Yancopoulos (Regeneron Pharmaceuticals, Tarrytown, NY). Ribosomal 7S RNA was used as a loading control.
MMP-2 and TIMP-2 expression
Tumor extracts were incubated with gelatin-Sepharose 4B, and MMPs were eluted with buffer containing 10% DMSO. Samples were subjected to zymography in gels containing 1 mg/ml porcine gelatin, and gels were subsequently incubated and stained with amido black as previously described (23) . Western blotting was performed with antibodies against MMP-2 and TIMP-2 (both from Chemicon, Temecula, CA) and subsequent luminography.
CB 1 and CB 2 receptor expression
Western blot analysis of cannabinoid receptors was performed in cell membrane fractions as previously described (8) . The anti-CB 1 receptor antibody was kindly given by Dr. K. Mackie (University of Washington, Seattle, WA). The anti-CB 2 receptor antibody was from Cayman Chemical (Ann Arbor, MI).
ERK activity
ERK activity was determined in cell extracts as the incorporation of [γ-
32 P]ATP into a specific peptide substrate as previously described (8) .
Statistics
Results shown represent means±SD. Differences among groups were evaluated by the unpaired Student's t test or ANOVA, with a post hoc analysis by the Student-Neuman-Keuls test.
RESULTS
Two different cannabinoid receptors have been characterized and cloned from mammalian tissues: the "central" CB 1 receptor, which is responsible for cannabinoid psychoactivity (24) , and the "peripheral" CB 2 receptor, which is unrelated to cannabinoid psychoactivity (25) . Because cannabinoid-based therapeutic strategies should be as devoid as possible of psychotropic side effects, we administered to tumor-bearing mice the selective CB 2 agonist JWH-133 (19) . We have recently provided pharmacological, biochemical, and behavioral evidence that JWH-133 activates selectively the CB 2 receptor in the present experimental system (9).
Cannabinoid administration inhibits tumor angiogenesis
As reported before (9), JWH-133 administration inhibited the growth of C6-cell (Fig. 1A ) and human gliomas (Fig. 1B ) in mice. In addition, whereas control tumors had a reddish color, cannabinoid-treated tumors had a pale appearance (Fig. 1A and 1B ), suggesting that a deficient blood supply might be a cause for such growth inhibition. Analysis of the vasculature by immunostaining of CD31, a marker of endothelial cells, revealed no significant effect of JWH-133 administration on microvascular count (number of blood vessels per unit area) in the tumors (data not shown). However, we observed a notable effect of cannabinoid administration on blood vessel morphology. Thus, in control animals, C6-cell gliomas displayed microvascular hyperplasia, in which proliferating blood vessels are lined by disorderly heaped up endothelial cells that ultimately transform into glomeruloid tufts (Fig. 1C) . Similarly, control human astrocytomas showed a network of dilated immature vessels (Fig. 1E) . In contrast, all JWH-133-treated tumors showed a pattern of blood vessels characterized predominantly by very small and narrow capillaries (Fig. 1D and 1F ).
We subsequently analyzed the expression of smooth muscle α-actin (SMA), a marker of smooth muscle cells and pericytes. In control tumors, SMA-positive cells were detached from the endothelial cells that constitute the walls of the blood vessels, pointing to the disruption of the normally stable link of endothelial and perivascular cells (Fig. 1G) . This process is known to occur during active tumor growth (26) (27) (28) . In contrast, in JWH-133-treated tumors, SMApositive cells had a mature appearance and remained closely around the endothelial wall (Fig.  1H) . This high and well-defined coverage of smooth muscle cells and pericytes is indicative of a differentiated vascular phenotype (26) (27) (28) .
We next examined whether these changes in tumor vascularization in vivo lead to actual differences in vascular functionality as assessed by a vascular permeability assay. Dye accesibility to the tumors was much lower in cannabinoid-treated animals than in controls ( Fig.  2A and 2B) . Analysis of the in situ-tumor pictures showed that the dye extravasation area in the tumor relative to total tumor area was 84±11% in control animals and 15±7% in JWH-133-treated animals for C6-cell gliomas (n=4, P<0.01) and 88±19% in control animals and 21±11% in JWH-133-treated animals for human astrocytomas (n=4, P<0.01). These observations, together with the CD31/SMA staining data, indicate that the vascular network of actively growing control tumors is large, plastic, and leaky, whereas that of slowly growing cannabinoidtreated tumors is small, differentiated, and impermeable.
Cannabinoid administration inhibits vascular endothelial cell migration
We examined the direct impact of cannabinoids on vascular endothelial cell migration and survival. Primary HUVECs expressed the two subtypes of cannabinoid receptors (Fig. 3A) . The mixed CB 1 /CB 2 cannabinoid agonist WIN-55,212-2 (25 nM) inhibited HUVEC migration as assessed by the Boyden chamber method and by scratch coverage, and this effect was prevented by the CB 1 selective antagonist SR141716 (0.5 µM) and the CB 2 selective antagonist SR144528 (0.5 µM) (Fig. 3B and C) , pointing to the involvement of cannabinoid receptors. Moreover, selective activation of the CB 2 receptor with JWH-133 (25 nM) also blocked cell migration (Fig.  3B) . Similar inhibitory effects of WIN-55,212-2 and JWH-133 were observed when the cell migration stimulator (lysophosphatidic acid) was added to both wells of the Boyden chamber (data not shown), pointing to a real depression of cell locomotion (chemokinesis) rather than of chemotaxis.
We also tested the possible involvement of the extracellular signal-regulated kinase (ERK) cascade in cannabinoid action, because ERK seems to be involved in the control of cell function by cannabinoids in other cell types (29). Thus, cannabinoid receptor activation increased ERK activity in HUVECs (Fig. 3D) , and pharmacological blockade of the ERK cascade with the selective inhibitor PD98059 (25 µM) abrogated cannabinoid inhibition of cell migration (Fig.  3B) .
Cannabinoid administration induces vascular endothelial cell apoptosis
We next studied whether cannabinoids affect vascular endothelial cell survival. WIN-55,212-2 (25 nM) induced HUVEC death, and this effect was prevented by SR141716 (0.5 µM) and by SR144528 (0.5 µM) (Fig. 4A) , pointing again to the involvement of cannabinoid receptors. Cannabinoid-induced HUVEC death occurred by apoptosis, as determined by oligonucleosomal DNA fragmentation (Fig. 4B) and TUNEL staining (Fig. 4C) .
The HUVEC line ECV304 was used to further study the pharmacological profile of cannabinoidinduced vascular endothelial cell death. Preliminary experiments had shown that, like HUVEC, the ECV304 cell line expresses the two subtypes of cannabinoid receptors (Fig. 3A) and ensues apoptosis upon activation of those receptors with WIN-55,212-2 ( Fig. 4D and data not shown) . The apoptotic effect of WIN-55,212-2 on ECV304 cells was mimicked by HU-210 (25 nM), another nonselective cannabinoid agonist, and by ∆ 9 -tetrahydrocannabinol (1 µM), the main active component of marijuana (Fig. 4D) . Moreover, selective activation of the CB 2 receptor with JWH-133 (25 nM) also induced cell death. PD98059 (25 µM (Fig. 4D) .
Cannabinoid administration inhibits tumor expression of proangiogenic factors
Tumor cells produce proangiogenic factors that promote the migration and survival of vascular cells (13) (14) (15) . Therefore, we next tested whether cannabinoids inhibit angiogenesis not only by targeting vascular endothelial cells directly, but also by interfering with proangiogenic factor expression in the tumors. In both C6-cell and human gliomas, VEGF and Ang2 expression was markedly reduced by JWH-133 treatment (Fig. 5A ). Ang1 expression was not affected by cannabinoid treatment (Fig. 5A ), in line with previous reports showing that this cytokine is not majorly involved in the pathogenesis of gliomas (26, 27) .
Cannabinoid administration improves other markers of tumor malignancy
The occurrence of abnormal vascular proliferation, aggressive invasion into surrounding normal tissue, and enhanced necrosis are general markers of progression of gliomas and other tumors (26) (27) (28) . In addition to its aforementioned action on angiogenesis, we found that cannabinoid administration improves those other two parameters of tumor malignancy. First, we determined MMP expression as a molecular marker for tissue breakdown and remodeling during malignant tumor growth (16) . In particular, we focused on MMP-2 because this protease plays a pivotal role in glioma invasiveness (30) (31) (32) and angiogenesis (31) (32) (33) . JWH-133 administration decreased MMP-2 activity and expression in C6-cell and human gliomas, whereas tissue inhibitor of metalloproteinase-2 (TIMP-2) expression was not affected (Fig. 5B) . Second, we observed that areas of necrosis with palisading nuclei, a factor that is considered predictive of a poor prognosis (27, 28) , appeared in control but not in JWH-133-treated tumors (Fig. 5C ).
DISCUSSION
Cannabinoids induce tumor regression in vivo (7) (8) (9) (10) . However, the exact mechanism of cannabinoid antitumoral action is still unknown. Here, we report that cannabinoids inhibit tumor angiogenesis in vivo and that at least two mechanisms may be involved in this cannabinoid action: direct inhibition of vascular endothelial cell migration and survival as well as suppression of proangiogenic factor and MMP expression in the tumors. A parsimonious interpretation of these and our previous findings (8, 9) is that cannabinoids inhibit tumor growth by activating cannabinoid receptors in both vascular endothelial cells and tumor cells. By inhibiting vascular endothelial cell migration and survival, cannabinoids would directly prevent blood vessel formation. By targeting tumor cells, cannabinoids would induce their apoptosis (8, 9) and would also suppress proangiogenic factor and MMP production, further blocking tumor growth and angiogenesis.
The observation that cannabinoids act directly on vascular endothelial cells is in line with recent reports showing that vascular endothelial cells express functional CB 1 receptors (34) that may be responsible for the hypotensive effects of cannabinoids in different pathophysiological situations (35) (36) (37) . Our data expand those findings by showing that activation of cannabinoid receptors modulates essential endothelial cell functions such as migration and proliferation. Of further therapeutic interest, here, we show that vascular endothelial cells--like glioma cells (9)--express functional CB 2 receptors. Hence, the present report--together with the possible implication of CB 2 or CB 2 -like receptors in the control of peripheral pain (38, 39) and multiple sclerosis-linked spasticity (40) , for example--opens the attractive possibility of finding cannabinoid-based therapeutic strategies devoid of nondesired CB 1 -mediated psychotropic side effects. Nevertheless, the existence in some blood vessels of non-CB 1 , non-CB 2 endothelial receptors for cannabinoids may not be ruled out (41) .
Cannabinoid administration was associated with a notable decrease in the expression of the major proangiogenic factors VEGF and Ang2, which are essential for the vascularization of gliomas and many other types of tumors such as those from mammary gland, lung, and skin (13, 22, 26, 27) . VEGF is likely the most important proangiogenic cytokine in health and disease, and Ang2, at least in the presence of VEGF, may also allow robust tumor angiogenesis and growth (13, 14, 26) . Thus, Ang2 is not expressed by normal human brain but is strongly induced in human gliomas (26, 27, 42) . Coinciding with high VEGF and Ang2 expression, vascular profiles are characterized by abnormal deposition of extracellular matrix and weak association with perivascular cells (26, 27, 42) . In addition, the failure of many solid tumors to generate a welldifferentiated and stable vasculature may indeed be attributed to a continuous overexpression of Ang2, which prevents vessel maturation and contributes to the generally plastic, tenuous, and leaky state of tumor vessels (26, 27, 42) . All this is precisely what we have observed in tumors from control animals (i.e., high Ang2 expression associated with enhanced MMP-2 activity, fractionated SMA staining, and increased vascular permeability), just the opposite occurring in cannabinoid-treated tumors.
In conclusion, our data show that cannabinoids inhibit the growth of gliomas in vivo by targeting both tumor cells and vascular endothelial cells. Gliomas are one of the most malignant forms of cancer, resulting in the death of affected patients within months after diagnosis. Current therapies for glioma treatment are usually ineffective or just palliative (43, 44) . One of the alternative therapeutic approaches might be based on the use of nonpsychoactive cannabinoid ligands, because these compounds inhibit tumor growth and angiogenesis in vivo. In line with the idea that antiangiogenic treatments constitute one of the most promising antitumoral approaches currently available (13, 14) , the present findings provide a novel pharmacological target for cannabinoid-based therapies. 
